TargetBeta
EPCAM
epithelial cell adhesion molecule · also Ly74, TROP1, GA733-2, EGP34 · CD molecules
3 programs in company-led studies act on EPCAM, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| adecatumumabrule | Mirador Therapeutics | phase 2 | 42 running | – | ChEMBL |
| Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314rule | BioNTech | phase 2 | 22 running | TNFRSF9 | NCIt |
| LTZ-232rule | LTZ Therapeutics | phase 1 | 11 running | – | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Colorectal Neoplasms, 2 programs
- Colonic Neoplasms, 1 program
- Inflammatory Bowel Diseases, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 30, 2027adecatumumab · Mirador Therapeutics · phase 2 · NCT07113522
- Dec 2030Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314 · BioNTech · phase 2 · NCT07079631
- Dec 2031LTZ-232 · LTZ Therapeutics · phase 1 · NCT07878988
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.